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Abstract A workshop was convened to discuss best prac-
tices for the assessment of drug-induced liver injury (DILI) in
clinical trials. In a breakout session, workshop attendees dis-
cussed necessary data elements and standards for the accurate
measurement of DILI risk associated with new therapeutic
agents in clinical trials. There was agreement that in order to
achieve this goal the systematic acquisition of protocol-speci-
fied clinical measures and lab specimens from all study subjects
is crucial. In addition, standard DILI terms that address the
diverse clinical and pathologic signatures of DILI were con-
sidered essential. There was a strong consensus that clinical and
lab analyses necessary for the evaluation of cases of acute liver
injury should be consistent with the US Food and Drug
Administration (FDA) guidance on pre-marketing risk assess-
ment of DILI in clinical trials issued in 2009. A recommenda-
tion that liver injury case review and management be guided by
clinicians with hepatologic expertise was made. Of note, there
was agreement that emerging DILI signals should prompt the
systematic collection of candidate pharmacogenomic, proteo-
mic and/or metabonomic biomarkers from all study subjects.
The use of emerging standardized clinical terminology, CRFs
and graphic tools for data review to enable harmonization
across clinical trials was strongly encouraged. Many of the
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Key Points
Graphic displays of study treatment population-level
data (study drug and comparator/placebo groups)
should be linked to individual graphic timelines that
depict serial biochemical measures in each study
subject with acute or worsening liver injury,
irrespective of the presumed etiology. Expert clinical
narratives and time-linked diagnostic studies that
provide valuable information for determining injury
phenotype and causality should be appended to these
graphic timelines
IT tools from sources such as CDISC should be used
in the preparation of clinical trial findings pertinent
to DILI analysis, in order to ensure complete and
uniformly collected data results
Emergence of cases of mild, moderate or severe liver
injury associated with a study drug should prompt
the preemptive collection of DNA from all study
subjects, both in the study drug and comparator
treatment arms. In addition, serum samples from all
study subjects obtained both before and during
treatment should be stored to enable the future
identification and study of candidate proteomic,
metabonomic and other soluble biomarkers or
predictors of DILI
Drug Saf (2014) 37 (Suppl 1):S19–S31
DOI 10.1007/s40264-014-0183-6
recommendations made in the breakout session are in align-
ment with those made in the other parallel sessions on meth-
odology to assess clinical liver safety data, causality assessment
for suspected DILI, and liver safety assessment in special
populations (hepatitis B, C, and oncology trials). Nonetheless, a
few outstanding issues remain for future consideration.
1 Introduction
A workshop jointly sponsored by the Hamner-University of
North Carolina Institute for Drug Safety Sciences and the
European Innovative Medicines Initiative on best practices
for the assessment of drug-induced liver injury (DILI) in
clinical trials was convened in Boston, Massachusetts on
November 9, 2012 [1]. Achieving an accurate early
assessment of risk surrounding DILI in clinical trials con-
tinues to present a series of critical challenges for the
developers of new drugs and biological agents, as well as
government regulators. From a public health perspective
there is a broad interest to (1) improve the quality, reli-
ability and consistency of risk evaluation in clinical studies
by diverse stakeholders, that include the large and small
manufacturers of synthetic drugs and biological agents,
academic investigators, governmental regulatory scientists
and reviewers of New Drug Applications; (2) encourage
broader enrollment of clinical study subjects who reflect
‘real-world’ patients, including those with different levels
of pre-existing necro-inflammatory disease and fibrosis of
the liver; (3) facilitate efficient and comprehensive regu-
latory review with attention paid to the impact on benefits
and risks surrounding a new drug in individuals with
increased susceptibility for the development of hepatotoxic
reactions to the agent; and (4) provide a sound basis for
aggregating data across drug development programs in
order to predict the effects of demographic factors, back-
ground diseases and concomitant treatments on DILI and
provide an expanding resource for pharmaceutical industry,
academic and government scientists to discover new pre-
dictive biomarkers of DILI in a precompetitive space.
These objectives form a rationale for the development of
best practices in data acquisition and analysis of hepato-
toxicity in clinical trials. They are prompted by major gaps
in the state of current knowledge to accurately assess the
causal association of hepatic injury with exposure to newly
developed study drugs or biological agents.
Species-dependent differences in xenobiotic metabolism
and regulatory pathways that determine toxic responses to
drugs have prevented a dependable extrapolation of drug-
related findings in animals to man. Currently, there are no
validated pre-clinical or clinical DILI biomarkers that
reliably predict which new drugs can cause idiosyncratic
DILI prior to occurrence of the actual events. In addition,
clinical biomarkers have not yet been identified that indi-
cate which patients are susceptible to serious DILI or
whether adaptation or progression of liver injury will ensue
after initiation of mild DILI. Second, DILI caused by dif-
ferent newly developed drugs may be caused by different
toxicological mechanisms and associated with distinct
clinical phenotypes as well as degrees of injury severity.
These differences would impact what clinical datasets
would be crucial to collect in clinical trials. Third, distinct
susceptibilities to DILI are often related to demographic
characteristics as well as baseline medical conditions in
different populations. Required investigations surrounding
an adequate evaluation of serious DILI cases in a clinical
trial population must always include diagnostic testing for
the systematic exclusion of all plausible competing etiol-
ogies for new-onset liver injury in similar patients, a
thorough evaluation of pre-existing medical conditions and
liver diseases, as well as the screening for relevant known
pharmacogenomic markers of DILI risk.
Unfortunately, to achieve consensus for best practices in
this arena there are a number of significant hurdles that must
be overcome. On the one hand, it is self-evident that from a
regulatory perspective, levels of refinement in the quantita-
tive risk evaluation surrounding DILI that are required to
adjudicate approvability of a new drug based on overall
benefits and risks will depend on the strengths of the overall
benefits. For example, the degree of quantitative precision
that is required to assess risk for rare idiosyncratic liver failure
surrounding a new treatment for a non-life threatening dis-
order of recurrent mild symptoms is higher than for a highly
malignant tumor with a poor prognosis. On the other hand, in
order to achieve uniform standards there is a necessity for
establishing consistency in nomenclature and equivalency in
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data acquisition across drug development programs and
investigational units for clinical studies. Comparability in the
assessment of cases of hepatotoxicity across clinical trials in
similar treatment populations will strongly depend on the
development of common standards for the characterization of
clinical courses of DILI and diagnostic testing to exclude
non-drug related etiologies of liver injury.
This article discusses recommendations from a breakout
session at the workshop that was charged to consider
required data elements and best practices for data collec-
tion and standardization. The session paralleled others
whose recommendations are summarized in companion
articles on (1) methodology to assess clinical liver safety
data [2], (2) causality assessment for suspected DILI [3],
and (3) liver safety assessment in special populations
(hepatitis B, C, and oncology trials) [4].
2 Standardization of DILI Terms
Standardization of nomenclature that characterizes hepa-
totoxicity in both pre-clinical and clinical settings is a
prerequisite for establishing best practices in clinical trials.
Characterization of clinically significant cases of DILI
encompasses a need to define organ injury phenotype, the
level of clinical severity that includes measures of liver
function/dysfunction, and the level of likelihood of causal
association with the study drug. Recently, there have been a
number of international workshops and projects to establish
standardization of terms for these attributes, most with
reference to the characterization of hepatotoxicity caused
by exposure to a marketed drug in non-study outpatients
who are referred for evaluation [5–7]. In contrast, discus-
sion about a plan to develop best practices as envisioned in
this workshop specifically revolves around clinical trial
enrollees treated with study drugs under development.
In clinical trials there is a unique opportunity to com-
prehensively monitor and systematically evaluate all en-
rollees at different time points from the pre-treatment
phases to the end of the study. Generally, this assessment is
complemented by a thorough evaluation of findings gen-
erated from pre-clinical in vitro and animal test systems.
DILI has been linked to a diverse range of drug and
patient-specific pathological and/or clinical phenotypes and
profiles of laboratory abnormalities [7] (see Table 1),
implying that multiple potential mechanisms of injury are
responsible for inciting hepatotoxicity.
When appropriate, these terms can be used as phenotypic
descriptors of DILI cases in clinical trials. Establishing best
practices surrounding the use of these different descriptors
will require further discussion. In addition to hepatocytes,
other cell types, including biliary, sinusoidal and Kupffer
cells, may be damaged or contribute to the injury process.
Moreover, although DILI is often associated with acute
damage effects, in some instances it has also been linked to
subacute, persistent and chronic forms of injury.
With such a diversity of DILI phenotypes and clinical
signatures, it is self-evident that establishing rigorous
standards in nomenclature is critically important to achieve
best practices across drug development programs.
In conjunction with a requirement to adhere to precise
definitions of different clinically important states of liver
injury and levels of organ function/dysfunction in cases that
occur in clinical trials, it is also necessary to conform to
commonly adopted lab units (e.g. International Units/liter for
serum liver enzymes and mg/dl for bilirubin) and approaches
to establishing cut points between normal and abnormal
measurements of circulating liver enzymes. As drug-induced
hepatotoxicity in every individual is a dynamic process
which changes over time from initiation of liver injury to
progression or resolution, these definitions must incorporate
criteria defined by the timing and evolution of these events.
For example, the ratio of serum alkaline phosphatase (ALP)
to alanine aminotransferase (ALT) levels often may increase
over the course of acute liver injury.
Thus, since acute hepatocellular and cholestatic injuries
are defined by R values [ratios of ALT fold upper limit of
normal (ULN) 7 ALP fold ULN are greater than 5 and
less than 2, respectively], establishing a convention that
these should be measured at the onset of liver injury is
crucial. In addition, establishing criteria for cut-off bound-
aries between normal and abnormal values of liver enzymes
is critically important. In some instances, it is appropriate
that the distribution of values within a specific demographic
group or treatment population, if documented, should serve
as a frame of reference for the measurement of an upper
Table 1 Pathological and clinical phenotypes of DILIa
Acute hepatic necrosis
Acute viral-like hepatitis
Acute liver failure
Immunoallergic hepatitis
Autoimmune hepatitis
Cholestatic hepatitis
Bland cholestasis
Acute fatty liver & lactic acidosis
Nonalcoholic steatohepatitis
Nonalcoholic fatty liver
Chronic hepatitis
Nodular regeneration
Vanishing bile duct syndrome
Sinusoidal obstruction syndrome
Cirrhosis
DILI drug-induced liver injury
a Adapted from Fontana et al. [7]
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limit of normal. However, when study populations are
comprised of individuals with frequent and variable pre-
treatment elevations of liver enzymes, such as in clinical
trials to treat chronic viral hepatitis or non-alcoholic ste-
atohepatitis (NASH), population-based upper limits of
normal do not apply.
In the case of treatment trials for NASH, individual pre-
treatment baseline measurements of serum liver enzyme
and bilirubin may be optimal as reference levels to assess
subsequent acute liver injury. However, in treatment trials
for viral hepatitis the values of liver tests at their nadir,
after treatment-induced viral suppression has occurred,
may be more suitable as reference levels to assess possible
DILI, if liver indicators later rise with continued treatment.
These considerations are extensively discussed in a com-
panion article [4].
At the time of enrollment of patients with pre-existing
liver diseases, when should baseline measurements prior to
treatment with a study drug be performed? In developing
best practices, there has been general agreement that to
reliably measure baseline enzymes prior to the initiation of
a test drug, a minimum of two time points should be
sampled. Baseline measurements at more than one time
point are particularly important if the values of liver dis-
ease are likely to fluctuate as a result of the natural course
of pre-existing liver disease. One proposal that was made is
that these be performed during a clinical trial’s run-in
phase, just before the initiation of study drug treatment as
well as one month earlier.
Another consideration in adopting best practices for
measuring liver enzymes during clinical trials is the nat-
ure of the study drug. Certain drug groups, including
many classes of chemotherapeutic agents are marked by a
narrow therapeutic index. These products would be
expected to cause dose-related liver injury in many study
subjects in a range often close to or overlapping with
therapeutic dosing. With such drugs, studies of dose
response and duration of treatment effects on liver bio-
chemical indicators are vital. In addition, it is important to
identify extrinsic and intrinsic modifiers of study drug
exposure in the liver, as well as factors which predict
increased susceptibility to hepatotoxicity by the study
drug at lower doses.
3 Domains that Influence What Data Elements Should
be Collected and Standardized
The required elements of data acquisition and standards of
data management in clinical trials are influenced by the
clinical context in which each study drug will be used. To
optimize best practices for acquiring and managing nec-
essary data there are five interconnected domains that must
be harmonized. They are study design, data acquisition,
DILI case assessment & management, data management
and scientific and regulatory review. These domains
inform one another with regards to the required elements
they contain and can be modified for study drugs used in
certain clinical contexts.
3.1 Impact of Study Design on Necessary Data
Elements
Data required for a thorough analysis of DILI events in
clinical trials are impacted by study inclusion/exclusion
criteria. For example, when patients with a pre-existing liver
disease are recruited into studies, it is especially important to
accurately measure patient-level baseline values of all liver
enzymes and other liver tests (e.g. serum bilirubin and INR)
prior to treatment with the study drug. It was suggested at the
best practices workshop that samples should be obtained at
two or more time points one month apart in the pre-treatment
phase to determine if these parameters are constant or subject
to fluctuations. Because many drugs are metabolized and
cleared by the liver, pre-existing liver diseases may signifi-
cantly alter blood pK profiles, delivery rates of the drug to the
liver and/or other tissues, hepatocellular modifications of the
parent drug by phase I and II enzymes and/or secretion of the
drug products in phase III out of hepatocytes into the bile or
other extracellular compartments. Major disease-driven
perturbations at any one of these steps caused by liver disease
can have important effects on dose-dependent study drug
efficacy and/or risk for toxicity.
As described, these can be different, depending on the
pathological processes, clinical severity and chronicity of
the underlying liver disease. Thus, studies which identify
changes in study drug and drug metabolite exposure levels
due to reduced drug-protein binding in the circulation,
portosystemic shunting, alterations in the drug’s hepato-
cellular metabolism and clearance in a study population
with pre-existing liver disease are crucial for the evaluation
of risk factors for hepatotoxicity. In a similar vein, a
comprehensive assessment of drug-drug interactions that
alter the uptake, metabolism and clearance of study drugs
metabolized and/or cleared by liver cells is necessary if
there is a toxic exposure threshold that may be crossed.
Finally, change-of-function genetic polymorphisms of a
study drug transporter protein or metabolizing enzyme, and
proteins which determine hepatic immune responses to the
drug (e.g. major histocompatibility complex Class I and II
molecules) take on special importance when cases of DILI
caused by ‘intrinsic’ factors are identified in clinical trials.
When genomic variants are discovered in a rigorously
scientific manner to be associated with susceptibility to
study drug-specific DILI there may be a future opportunity
to screen patients as an aid in patient risk management.
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With reference to best practices, to evaluate perfor-
mance characteristics of putative genetic markers the
workshop attendees concluded that it is critically important
to systematically collect DNA biospecimens from all study
subjects, including controls treated with a comparator/
placebo, as well as those treated with the study drug who
do not develop DILI.
3.2 Protocols for Data Acquisition
Taking study design and study enrollment criteria into
account, it is essential to include detailed pre-specified
instructions in clinical study protocols with comprehensive
listings of all the clinical measurements and assays that
should be performed at baseline and during treatment with
the study drug/comparator in conjunction with detailed
timelines that describe when and how biospecimens
should be obtained, and handled by site investigators.
Detailed protocols of required tests and clinical data
should be provided for all study subjects and separately
for all study subjects who develop acute liver injury or
worsening of liver injury during treatment with the study
drug or comparator with follow-data until the end of the
study period (see Sect. 3.3). Protocols should also include
a plan(s) to utilize expert internal and/or external consul-
tation available to each drug developer to provide timely
guidance on obtaining sufficient data for the comprehen-
sive characterization of clinical phenotype and etiology as
well as for effective ‘real-time’ clinical management of all
cases of acute liver injury occurring during treatment with
the study drug or comparator. If an emerging liver ‘signal’
comprised of cases of mild, moderate or severe liver injury
is associated with a study drug, preemptive collection of
genomic biospecimens from all study subjects in large
clinical trials of the drug should be performed. In addition,
serum samples obtained both before and during treatment
of all study subjects should be stored to enable the future
study of new proteomic, metabonomic and other soluble
biomarkers or predictors of DILI (see below). In special
circumstances, when there is a rising concern that a study
drug may cause serious DILI, it may be necessary to
unblind study subject treatment assignments of individuals
with etiologically undiagnosed liver injury before the
study is terminated.
Clinical development programs for drugs that will likely
be used to treat patients with increased susceptibility to
serious DILI after marketing has begun should contain
sufficient data to identify and characterize important ‘risk
factors’ and drug exposure effects. Target treatment pop-
ulations that may be associated with an increased risk for
DILI include patients with pre-existing liver disease,
unique demographic risk-related characteristics, use of
concomitant drugs responsible for potentially toxic drug-
drug interactions with the study drug, reduced drug clear-
ance, or genomic markers of increased risk.
3.3 Protocols for DILI Case Assessment
and Management
As described above, complete protocols in clinical trials
must provide instructions to obtain all required data ele-
ments that will enable full assessment of all cases of new
onset or worsening liver injury. There are three broad
reasons to establish a detailed map for clinical investigators
to follow to obtain necessary data elements. First, it will
provide a basis to mitigate risk for serious outcomes in
individual study subjects with DILI based on prognostic
considerations. Time-sensitive actions to optimally manage
DILI include discontinuation of the study drug in a timely
manner, avoiding re-challenge, modification of dosage,
performance of time-sensitive diagnostic tests and institu-
tion of therapeutic interventions. Second, after evaluation
of all DILI cases in the clinical trial database, it will pro-
vide a sound basis to predict risk for clinically serious DILI
in post-market treatment populations based on analyses of
phenotype, clinical severity, DILI incidence in the study
population and identified factors tied to increased DILI
susceptibility. Third, once uniform practices in data col-
lection are adopted there will be a growing opportunity to
aggregate data across clinical trials to facilitate the research
of DILI.
3.4 FDA Guidance on Pre-Marketing Assessment
of DILI as a Frame of Reference for Best Practices
A guidance on pre-marketing risk assessment of DILI in
clinical trials was issued by FDA in 2009 [8]. FDA guid-
ances generally do not establish legally enforceable
responsibilities for industry, unless specific regulatory or
statutory requirements are present. Rather, they describe
the agency’s thinking on a topic and provide suggestions
and recommendations. These can later be revisited and
refined after careful science-based deliberation by FDA
with stakeholders. Since the best practices workshop was
convened by non-FDA parties, conclusions drawn by
attendees do not represent an FDA position and should not
be construed as replacing the 2009 guidance. At the
workshop, there was a consensus that from a best practices
perspective, points previously made in the FDA guidance
pertinent to DILI case evaluation and management have
proven very useful and should be followed. The guidance
should be referred to directly, for this purpose.
In brief, the FDA guidance has emphasized that by
definition Hy’s Law cases are marked by serious hepato-
cellular injury for which after an appropriate work-up for
possible alternative causes the study drug has been
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identified as the most likely cause. The term ‘Hy’s Law’
refers to an original observation made by the late Dr.
Hyman Zimmerman that at least 10 % of patients who
develop jaundice caused by drug-induced hepatocellular
toxicity will develop liver failure. As described in the 2009
guidance, biochemical criteria consistent with Hy’s Law
include elevations of serum ALT or AST [ 3X ULN,
accompanied by increases of serum bilirubin levels [2X
ULN that occur concomitantly or ensue within a one-month
period. Since the hepatic injury associated with Hy’s Law is
hepatocellular and not cholestatic in nature, the guidance
notes that peak ALP levels are characteristically\2X ULN.
Moreover, R values [ALT 7 ALP (fold ULN)] [5 are
consistent with hepatocellular DILI, as defined by an
international consensus [5, 6]. The presence of Hy’s Law
cases in a pre-approval clinical trial database raises sub-
stantial concern that post-marketing liver failure cases
associated with the study drug are likely to occur, assuming
that the incidence and prognostic implications of these
events can be projected into a large treatment population.
Attendees at the workshop agreed that new retrospective
studies of liver safety databases for drugs known to have
risk of causing liver failure would provide valuable
opportunities to further investigate this link. Isolated serum
ALT elevations often resolve even with continuation of
treatment with an idiosyncratic hepatotoxic agent. Thus,
such transient enzyme elevations, particularly those that are
low or moderate, have little prognostic value. Since it is not
yet possible to identify that small subset of study subjects
with mild DILI marked by rises of aminotransferases who
will fail to adapt to the study drug and progress to life-
threatening forms of liver injury, the FDA guidance has set
criteria that trigger a requirement for follow-up and evalu-
ation of study subjects who develop abnormal test results as
well as ‘stop-treatment’ recommendations that are conser-
vative in favor of subject safety. The guidance stipulates
that subjects who develop serum aminotransferase (AT)
increases [3X ULN should be followed by repeat serum
liver testing within 48–72 h. If repeat testing demonstrates
that AT levels remain [3X ULN, or [2X pre-treatment
values for subjects with elevated levels before study drug
exposure, the guidance recommends close observation that
includes elicitation of a detailed history and performance of
diagnostic lab studies to exclude other causes of acute liver
injury. In addition, continued liver testing 2–3X /week is
recommended until resolution or return to baseline values of
liver test results. Unfortunately, in the guidance there are
notable gaps in setting criteria for initiating close observa-
tion of study subjects with pre-existing liver diseases
marked by high baseline AT measures.
The guidance also recommends that the study drug be
immediately stopped when any of the following results are
obtained by the site investigator: 1. ALT or AST [ 8X
ULN; 2. ALT or AST remains[5X ULN over 2 weeks; 3.
ALT or AST [ 3X ULN & total bilirubin [ 2X ULN or
INR [ 1.5; 4. ALT or AST [ 3X ULN with symptoms
(e.g. fatigue, nausea and vomiting, right upper quadrant
pain, fever, rash) or eosinophilia. The guidance also rec-
ommends that if an earlier episode of hepatotoxicity with
the study drug has occurred rechallenge should be avoided
unless there are no other good therapeutic options.
To evaluate individual cases of hepatic injury in clinical
study subjects, the guidance has set forth a series of rec-
ommendations. First, it enumerates all of the critical ele-
ments that should be ascertained for characterizing cases of
liver injury and incorporated into the case report forms
(CRFs) of subjects, either treated with the study drug or
comparator in order to fully describe the events, as well as
demonstrate results of a complete battery of diagnostic
studies. These are incorporated into Table 2.
Second, it has set forth recommendations to check for
clinical correlates and perform diagnostic tests in subjects
with possible study drug-induced hepatotoxicity that
exclude all the main alternative causes of liver injury (see
Table 3).
Finally, the guidance makes recommendations for the
overall assessment of liver-related adverse events in a
clinical trials database, once studies of a new drug candi-
date are completed in preparation of a New Drug Appli-
cation or Biologic License Application. These
recommendations include assessment of the metabolism of
the study drug and measurement of the incidences of liver
injury, in individual trials and in the entire clinical trial
database, with stratification by levels of severity, as defined
both by biochemical and clinical parameters. Descriptions
of these strata are incorporated into Table 5. Submissions
to FDA should also contain narrative summaries of all
cases marked by biochemical parameters conforming to
Hy’s Law that include extensive demographic, clinical and
laboratory data to achieve comprehensive differential
diagnoses and causality assessments.
3.5 Workshop Discussion on Acquisition of Critical
Data Elements
The workshop attendees concluded that best practices
being considered to evaluate DILI in clinical trials should
support and maintain consistency with recommendations in
the FDA guidance. In concert with the FDA guidance, the
workshop concluded that a number of additional best
practice measures are in order. Many of these proposed or
considered measures are summarized in the tables as
italicized comments. First, in Phase I studies of new drugs
serum liver chemistry testing should be conducted in all
study subjects exposed to the drug on a frequent basis (at
least every 2 or 3 days during the study period). Second,
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critical elements for characterizing cases of liver injury in
all study subjects should include sequential measurements
of a core of clinical and laboratory parameters in cases of
serious liver injury, at specified phases of hepatic injury
and recovery (see Table 2). When needed, consultation
with a clinical subject matter expert is recommended to
guide the performance of necessary additional diagnostic
studies. Third, biochemical testing of serum samples for
liver indicators that determine whether the study drug
should be continued, discontinued or undergo dose modi-
fication should be performed in local labs at each investi-
gator site, in order to expedite timely risk management
decisions surrounding study subjects. Separate testing of
duplicate serum samples should later be performed in
clinical study central labs to ensure consistency in the
follow-up analyses and scientific reviews of the data.
Table 2 Critical Elements for Characterizing Cases of Liver Injury in Clinical trialsa
Elements Comments
Demographics (age, gender, ethnicity, race)
Study drug/comparator
Start of study drug/comparator to start of liver abnormalities/
illness (times & dates)
Study drug/comparator cessation, interruption or dose change
(times & dates)
Study drug pretreatment liver test values Serum ALT, AST,
ALP, bilirubin (total/direct), INR
Normal ranges should be provided. In study populations with frequent and
variable pre-treatment elevations, baseline testing should be performed at
least twice, one month apart
Description of liver injury: Clinical symptoms, signs, other
organ involvement, lab findings
Should include time-based liver test results at pre-treatment & q 2-4 wk
treatment time points. After onset of abnormalities (AT [ 3 XULN or 2X
baseline), include results of more frequent testing q 3–4 days until
values stabilize with continued drug treatment or upon discontinuation,
& follow-up tests performed until resolution of liver injury. Local &
central lab results should be separately recorded and included in
database. Lab tests to rule out non-DILI causes are summarized in
Table 3. Dates of sampling for these tests should be recorded
Outcomes of liver injury Includes recovery, hospitalization, liver transplant, death
Medical conditions/risk factors for liver diseases (e.g. EtOH
exposure, DM, obesity, hypertriglyceridemia)
Includes genomic test results of known markers of increased risk for liver
diseases or study drug-specific DILI
Each co-med & CAM: dose, start & stop dates, information on
de- or re-challenge
Needs careful questioning of study subject or family members
Evaluation of non-drug causes See Table 3. Pre-study results (e.g. serological markers, etc.) should also
be included to enhance interpretation of tests for non-drug causes
performed after initiation of the study drug
Liver injury case narrative with free text describing time course
of all relevant clinical findings and biochemical test results,
including pre-treatment values, diagnostic workup &
interpretation
Narrative should be assembled by a clinician with a comprehensive
knowledge of diagnostic hepatology & DILI
Supplementary information: Consults, Special tests Expert consultation is recommended to provide timely guidance for
appropriate tests together with input on clinical management &
interpretation of serious liver injury cases
Identification of Predictive Biomarkers In case of an emerging association of liver injury with the study drug, the
collection and storage of genomic DNA from all subjects (both study
drug and control groups) for subsequent assessment of genomic
susceptibility to DILI is recommended. Similarly, serum and urine
samples systematically obtained from all subjects after treatment
initiation with study drug or comparator may be subsequently used to
study proteomic, metabonomic & other soluble markers or predictors of
DILI
AT aminotransferase, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, INR international normalized
ratio, DILI drug-induced liver injury, EtOH ethanol, DM diabetes mellitus, CAM complementary and alternative medicine, ULN upper limit of
normal
a The elements primarily follow the FDA guidance on drug-induced liver injury: premarketing evaluation (2009) [8]. These should be provided in
Case Report Forms. Detailed study design protocols should provide instructions for the acquisition of key clinical data and lab tests for all study subject
enrollees and separately for individuals who develop DILI or worsening of liver injury during treatment with the study drug or comparator
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Fourth, narratives of all clinically significant acute or
worsening liver injury cases in study subjects receiving
study drug or comparator/placebo, including those with
biochemical abnormalities conforming to Hy’s Law,
should be assembled by clinicians with an in-depth
knowledge of diagnostic hepatology to facilitate an
informed evaluation and the effective communication of
both clinical case characteristics and causality of liver
injury to academic and regulatory scientists. To enhance
transparency and contextualization of the liver findings in
clinical trials, graphic displays of peak liver test results of
all study subjects should be uniformly provided, in con-
junction with detailed time-based displays of the changing
biochemical parameters for each individual manifesting
acute or significant worsening of liver injury during treat-
ment with the study drug or comparator/placebo. Each
study-subject level graph should be linked to its
corresponding clinician-assembled case narrative. A com-
panion article describes the graphic tools in more detail [2].
Finally, in drug development programs of agents with an
emerging liver injury signal (pre-clinical findings of liver
toxicity or drug-related increases of serum ATs in clinical
study subjects) or in a class containing hepatotoxic drugs
there is a unique opportunity to preemptively bank DNA of
study subjects receiving the study drug as well as controls,
using methods that conform to legal and ethical standards.
The FDA has issued a new guidance in January 2013 on the
premarket evaluation of clinical pharmacogenomics during
early-phase clinical studies [9]. This guidance provides
recommendations on when and how genomic investiga-
tions should be considered to address questions arising
during drug development and regulatory review. In keeping
with the general principles that are outlined in the guid-
ance, should clinically serious hepatotoxicity turn out later
Table 3 Alternative Etiologies of Liver Injury other than Study Drug in Clinical Trialsa—the bolded items represent the minimal data to be
collected
Diagnostic categories Diagnostic tests &/or clinical correlatesb
Acute viral hepatitis, Types A, B, C, D (if B is
present), and E
IgM anti-HAV; HBSAg, IgM anti-HBc, HBeAg, HBV DNA; anti-HCV, HCV RNA; anti-
HDV, IgM & IgG anti-HEV, HEV RNA
Other infections: EBV, CMV, HSV, Varicella,
Parvovirus, Toxoplasmosis
IgM & IgG anti-EBV; IgM & IgG anti-CMV; IgM & IgG anti-HSV, HSV DNA; IgM & IgG
anti-Varicella; IgM & IgG anti-Parvovirus; Toxoplasma gondii serological profile
Alcoholic hepatitis AST, ALT, WBC, PMN, Hx of EtOH
Autoimmune hepatitis ANA & ASMA titers, Total IgM, IgG, IgE
Nonalcoholic steatohepatitis AST, ALT, liver histology
Hepatobiliary disorders ALP, ALT; Bilirubin; Liver & biliary track imaging (US or CT scan; MRI & ERCP as
appropriate)
Cardiovascular causes Acute & chronic CHF, hepatic venous occlusion
Ischemic hepatitis Hypotension, right sided heart failure, hypoxia, LDH
Concomitant treatments Other prescription or OTC drugs, Herbals and dietary supplements, acetaminophen;
acetaminophen levels and adducts; drug-drug interactions
Other liver diseases Serum and 24-hour urine ceruloplasmin, slit-lamp exam, liver biopsy, serum ferritin, iron-
binding capacity
Other organ injuries CPK, LDH, creatinine
Comments Consultation with a clinical expert should guide appropriate additional diagnostic testing.
Dates when viral, serological & other diagnostic tests are performed must be recorded &
appropriately correlated with different phases of liver injury. Serum samples during the
acute and resolution phases of liver injury should also be stored to enable the post-hoc
performance of diagnostic tests not pre-specified in the study protocol. In special cases,
liver histopathology may provide important diagnostic information. Although often not
required in the evaluation of possible DILI cases, in some instances the availability of liver
tissue specimens or pathology reports can be helpful
WBC white blood cells, PMN polymorphonuclear neutrophils, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline
phosphatase. CPK creatine phosphokinase, LDH lactate dehydrogenase, DILI drug-induced liver injury, EBV Epstein-Barr virus, CMV cyto-
megalovirus, HSV Herpes Simplex virus, HAV Hepatitis A virus, HBV Hepatitis B virus, HCV Hepatitis C virus, HBSAg Hepatitis B surface
antigen, anti-HBc Hepatitis B core antibody, HDV Hepatitis D virus, HEV Hepatitis E virus, ANA anti-nuclear antibody, ASMA anti-smooth
muscle antibody, CHF congestive heart failure, OTC over-the-counter, US ultrasound, CT computed tomography, MRI magnetic resonance
imaging, ERCP endoscopic retrograde cholangiopancreatography
a The diagnostic categories listed in this table primarily follow the FDA guidance on drug-induced liver injury: premarketing evaluation (2009)
[8]
b Results obtained from this partial list of diagnostic tests and clinical correlates will facilitate the inclusion or exclusion of the corresponding
diagnostic categories. Depending on context, the performance of some tests may not be suitable for the evaluation of all cases
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to be causally linked to the study drug, banked DNA
samples can be retrieved and analyzed to identify predic-
tive biomarkers of increased susceptibility to DILI. It is
recommended that informed consents with collection and
storage of genomic DNA (e.g. blood or buccal cell DNA)
be obtained from all study subjects (study drug and control
groups). Expanding on this concept, serum samples sys-
tematically obtained before and after the initiation of
treatment could be similarly banked to enable the later
study of proteomic, metabonomic and other soluble
markers or predictors of DILI. Urine samples could like-
wise be stored for the study of metabonomic markers.
The workshop determined that in keeping with the FDA
guidance a comprehensive battery of tests for alternative
etiologies of liver injury should be performed (see
Table 3). In addition, serum samples during the acute and
resolution phases of liver injury should be stored to enable
the post-hoc performance of diagnostic tests other than
those specified in the study protocol. In one case in which
the retrospective serological testing established an alter-
native etiology of acute liver injury a clinical study subject
with a possible diagnosis of DILI was found to have acute
Type E viral hepatitis. Consistent with the FDA guidance,
the workshop concluded that liver biopsies are only rec-
ommended if clinically indicated. In possible cases of acute
DILI, they are generally not required to establish an
alternative diagnosis. However, in special cases, liver his-
topathology may provide important diagnostic information,
and the availability of liver tissue specimens or a pathology
report may be useful. For this reason, when liver biopsies
are performed, they should be stored and retrievable to
enable post-hoc case evaluation.
3.6 Monitoring and Management of Study Subjects
with Pre-existing Liver Disease
The workshop established that enrollment of study subjects
with pre-existing stable chronic elevations of ATs due to
pre-existing liver disease is acceptable (see Table 4), but
only in the absence of increased serum bilirubin or evi-
dence of end-stage cirrhosis.
In brief, it was felt that subjects being studied for the
treatment of oncological diseases with tumor involvement
of the liver marked by stable elevations of serum ATs and
ALP should be included in studies, if similar patients would
be likely to receive treatment with the same drug in a post-
market setting. Moreover, in contrast to a general recom-
mendation to exclude enrollment of patients with both
hyperbilirubinemia and serum AT elevations in clinical
trials of agents being developed to treat non-malignant
conditions, the presence of tumor-associated hyperbiliru-
binemia with or without AT elevations would not neces-
sarily disqualify study candidates from inclusion in clinical
studies of anti-tumor agents. The workshop also determined
that study subjects with pre-existing liver disease should
only receive study drug if baseline liver test results obtained
at two or more time points approximately one month apart
show no major changes. As a frame of reference for the later
monitoring of liver tests during treatment with the study
drug, the baseline levels of each of the biochemical indi-
cators would be computed as the means of these time-sep-
arated pre-treatment measures. In the event that any of these
indicators increase to levels [2X above the nadir values
during treatment with study drug, suggesting worsening
liver injury consistent with possible DILI, confirmation and
increased observation should be initiated, as outlined in the
FDA guidance. Treatment stop rule options in the face of
rising AT levels during treatment with a study drug in
special populations with pre-existing liver diseases were
discussed and are summarized in a companion article [4]. A
consensus was not reached among meeting attendees with
regards to endorsement of a specific set of instructions for
discontinuation of treatment in these patients. The work-
shop concluded that a series of analyses of cases with new
onset or worsening liver injury in clinical trial databases of
the study subjects should be performed (see Table 5).
Table 4 Analysis & Management of Study Subjects in Special Populations with Pre-existing Liver Abnormalities in Clinical Trialsa
Study exclusion criteria Individuals with stable elevations of ATs &/or ALP with increased levels of total bilirubin should be excluded from
most studies. Patients with confirmed Gilbert’s syndrome (indirect hyperbilirubinemia) may be permitted entry. In
addition, patients with tumor-associated hyperbilirubinemia, with or without elevations of ATs, in clinical trials for
cancer therapy may be permitted entry
Baseline serum liver
tests
Should be performed at least twice, one month apart. The baseline is computed as the mean value of a study subject’s
pre-treatment test results
Discontinuation of Study
Drug
Stop study drug if study subject develops increased bilirubin[2 X ULN with raised AT [ 3 X ULN. In the presence
of rising AT levels alone, there was no consensus among meeting attendees regards stopping rules during
treatment, as described in a companion article [4]
AT aminotransferase, ALP alkaline phosphatase, ULN upper limit of normal
a Liver abnormalities include conditions such as hepatitis B and C, and neoplasms in the liver. The issue is further discussed in a companion
article [4]
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Consistent with the FDA guidance, these assessments
should stratify cases based on levels of liver injury severity
and then compare equivalent strata of the trial enrollees
treated with study drug versus placebo or comparator
agents. The workshop also determined that strata of interest
would be defined by the fold increases of liver tests results
above the upper limits of normal. In studies of patients with
pre-study liver test abnormalities, these strata would be
defined by the fold increases of each individual’s baseline
test results, as described in Table 4. Significant associa-
tions of these stratification groups with demographic
characteristics, study drug dosing, other treatments,
underlying conditions or other lab measures should be
identified. If candidate DNA markers of DILI susceptibility
have been identified by genome-wide association studies
(GWAS) or targeted gene analysis (TGA), each stratum
should be separately analyzed for the strength of this
association.
3.7 Critical Diagnostic Tests and Time Course Data
As mentioned above, recent workshops have been con-
vened to discuss standards and acquisition of valuable data
elements pertinent to assessment of liver injury cases
associated with exposure to a marketed drug in non-study
outpatients who are referred for evaluation. Data elements
deemed important for publication of cases previously
identified by the NIH DILIN [10] and highlighted in the
Liver Tox website [11, 12] are included in Table 6.
These were also considered to be important by the
workshop attendees for DILI assessment in clinical trials.
The workshop also discussed the utility of testing acet-
aminophen (APAP)-derived adducts on samples obtained
from study subjects in which APAP overdose is suspected
(e.g. when very high AT levels are detected). Serum
gamma-glutamyl transferase (GGT) often rises in isolation
or in concert with elevations of ALP or as a result of high
ethanol exposure or after treatment with some cellular
enzyme-inducing drugs. The workshop did not draw a firm
conclusion about the value of this indicator to characterize
DILI cases in clinical trials. With emerging pharmacoge-
nomic markers of increased susceptibility to drug-specific
DILI, relevant genomic test results, if available, should also
be included as valuable data elements in the summaries of
possible DILI cases in clinical trials. A key concept for best
practices in the acquisition of critical data elements during
clinical trials is that in such a prospective study setting
there is a unique opportunity to serially gather both liver-
Table 5 Stratification of Cases of Liver Injury in Study Subjects treated with Study Drug or Comparator in Clinical Trial Database
Strata of interesta in trials of patients without pre-study liver test abnormalitiesb Strata of interesta in trials of patients with pre-study AT or
ALP abnormalities
3X, 5X, 10X & 20X ULN of ALT or AST, or both 2X, 3X, 5X, 10X & 20X baselinec ALT or AST, or both
Any elevation of bilirubin; elevated total bilirubin [2X ULN In cancer studies of subjects with tumor-induced elevated
bilirubin: [1X, [2X baseline bilirubin;
Elevation of ALP [ 1.5 ULN 2X, 3X, 5X, 10X & 20 X baseline ALP
Elevation of AT ([3X ULN) together with increased bilirubin ([1.5 ULN, [2X
ULN)
2X, 3X, 5X, 10X & 20 X baseline ALT or AST, or both,
together with elevated bilirubin
Elevated AT with symptoms including nausea, vomiting, anorexia, abdominal pain,
or fatigue
2X, 3X, 5X, 10X & 20X baseline ALT or AST, or both
with symptoms
Liver related serious outcomes including possibly liver-related treatment
discontinuations, hospitalizations, special medical interventions, liver transplants
&/or deaths
Comments:
Normal ranges of tests should be provided. Incidence in each stratum should be
calculated for study drug, placebo & active comparator groups. Time-to-event
analyses should be provided; Any association of the liver injury stratification
groups with gender, age, drug dose or regimen, concomitant drugs, underlying
disease or other lab measurements should be evaluated. If DNA samples from
study subjects (See Table 2) point to an association of DILI with a candidate
genomic marker (genome wide association study or targeted gene analysis), each
strata can then be analyzed for the strength of the association.
AT aminotransferase, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, ULN upper limit of normal, DILI
drug-induced liver injury
a Analyses are not limited to these strata
b Peak liver test abnormalities measured during study treatment. The listed strata of study subjects without pre-existing liver abnormalities
primarily follow the FDA guidance on drug-induced liver injury: premarketing evaluation (2009) [8]
c Pre-treatment test results of individual study subjects. These measurements are described in Table 4
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related clinical and biochemical data over a specified
sequence of time points, beginning at the study drug pre-
treatment phase, through phases of early, peak and late
phases of liver injury, and finally at the time of resolution
or stabilization of organ damage. The best practices
workshop concluded that for each study subject with acute
or worsening liver injury, irrespective of presumed
etiology, all serial liver tests and other relevant data ele-
ments that are clinical indicators and/or biochemical
measures of hepatic injury should be graphically displayed
on a timeline. In addition, the expert clinical narrative and
all time-linked diagnostic studies that shed light on injury
phenotype and causality should be appended to the graphic
displays of each study subject.
3.8 Data Management for Scientific and Regulatory
Review
Once data in clinical trials pertinent to DILI analysis have
been collected, there is a requirement to ensure that they
are complete, accurately tabulated and conform to
acceptable data standards. To this end, a number of
measures should be undertaken. These include adopting
standard representations of the data elements that are
consistent with a requirement in the Food and Drug
Administration Safety and Innovation Act (FDASIA). The
US law which was passed by the Congress in 2012 stip-
ulates that FDA must establish standardized clinical data
terminology for electronic submissions and standardiza-
tion of drug application data. After a draft guidance is
issued by FDA for stakeholders to provide comments on,
this objective is to be fully implemented by 2017, using
standardized clinical terminology developed by open
standards development organizations. One example of a
non-profit standards developing organization is the Clini-
cal Data Interchange Standards Consortium (CDISC) [13].
CDISC supports the development of data standards for
medical projects of any type, clinical study protocols, and
the specification and reporting of test results. IT tools
from sources such as CDISC should be used in the
preparation of clinical trial findings pertinent to DILI
analysis to ensure complete and uniformly collected data
results. In the case of CDISC, a Standard Data Tabulation
Model (SDTM) is used to repair erroneous or missing
data and ensure standardization of terms prior to sub-
mission of a drug or biologics application to regulatory
authorities for review.
The utilization of uniform data standards in Case Report
forms (CRFs) for DILI cases in each drug development
program and across programs is critical for the perfor-
mance of reliable and consistent clinical study reviews and
will enable user-friendly interfaces with other clinical lab
datasets in order to explore the effects of different variables
on liver injury and/or organ function. It will also encourage
further improvements in statistical and graphical tools that
are available for DILI analysis and readily usable by var-
ious stakeholders. Adoption of data standards during the
early planning stages of a clinical study will ensure uni-
formity of the data that will be later acquired and reduce
errors that can stem from post-hoc efforts to harmonize and
Table 6 Important Data Elements for Summaries of Possible DILI
Cases in Clinical Trialsa
Age
Sex
Weight
Study drug
• Name
• Daily regimen (dose, route and frequency of administration)
• Duration of protocol treatment
• Date of initiation of treatment
• Duration of treatment until onset of symptoms
• Duration of treatment until onset of abnormal test results
• Date of discontinuation or change of dose
Indication(s) for which study drug given
Other medical conditions at baseline
Medical events during treatment with study drug
Other medications taken during study
Other medications taken 2 months before study
Prior episodes of acute liver injury & causes
History of prior systemic & liver drug reactions
History of pre-existing chronic liver disease
Symptoms at the time of onset of liver injury
Physical findings at presentation
Initial lab test results: ALT, AST; ALP, GGT, Bilirubin (total,
direct), INR
Tests to exclude other causes of liver injury (see Table 2)
History of EtOH intake (drinks or grams per day during 12 months
before onset of event, EtOH dependence or abuse
Descriptions of other medical conditions, heart failure,
hypotension, sepsis, TPN
Serial lab tests until resolution of liver injury
Peak abnormalities of liver tests, INR
Clinical outcome(s) of liver injury
Time until resolution of symptoms
Time until resolution of lab test abnormalities
History of re-challenge or discontinuation
Acetaminophen levels & acetaminophen adducts if acetaminophen
overdose is suspected
Test results for previously identified genomic markers of increased
susceptibility to DILI
ALT alanine aminotransferase, AST aspartate aminotransferase, ALP
alkaline phosphatase, GGT gamma-glutamyl transpeptidase, INR
international normalized ratio, EtOH ethanol, TPN total parenteral
nutrition, DILI drug-induced liver injury
a Many of these elements coincide with those listed by LiverTox [12]
as important to include in publications of post-marketing case reports
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convert data. To standardize collection of data in CRFs,
CDISC is developing protocols for Clinical Data Acquisi-
tion Standards Harmonization (CDASH). The use of such
protocols developed by CDISC or other appropriate sour-
ces during the conduct of clinical studies increases the
likelihood of capture of complete and uniform data to
enable robust analyses of DILI events, as well as the
pooling of findings across trials.
Finally, harmonization and application of these analytic
tools will facilitate the accurate evaluation of study drug-
related DILI risk and enable exploratory investigations of
different factors that modify this risk. Standards-based
approaches will also provide a platform for the efficient
completion of comprehensive and reliable reviews by reg-
ulatory scientists and other stakeholders of large and com-
plex clinical trial datasets, while facilitating the downloading
of clinical and laboratory data into valuable graphic and
analytic programs (e.g. IT review instruments used by FDA
regulatory scientists, such as eDISH [14], Antiviral Infor-
mation Management System (AIMS) [15], SAS tools
including JMP Clinical [16] and MAED Service [17], R
statistical and graphical tools [18], and JReview [19]).
3.9 Highlights and Recommendations
1. Different DILI phenotypes should be referenced
using appropriate corresponding descriptors, as listed
in Table 1.
2. In clinical studies that enroll subjects with pre-
existing liver chemistry abnormalities, two or more
serum samples should be obtained over a one month
period in the pre-treatment phase to determine
whether the abnormalities are constant or changing.
3. When a candidate drug may later be associated with
DILI, the systematic collection of biospecimens for
DNA analysis should be undertaken from all study
subjects, including those treated with the study drug
who do/do not develop DILI as well as those treated
with the comparator or placebo.
4. Emergence of cases of mild, moderate or severe liver
injury associated with a study drug should prompt the
preemptive collection of DNA from all study
subjects, both in the study drug and comparator
treatment arms. In addition, serum samples from all
study subjects obtained both before and during
treatment should be stored to enable the future
identification and study of candidate proteomic,
metabonomic and other soluble biomarkers or pre-
dictors of DILI.
5. The retrospective examination of liver safety dat-
abases for drugs that are found to be causally
associated with liver failure in large treatment
populations would provide an opportunity to study
DILI susceptibility factors and further investigate the
link with any Hy’s Law cases observed in clinical
trials.
6. Biochemical testing of serum for liver indicators
should be performed at each investigator site to
expedite timely risk management decisions. Dupli-
cate samples should also be tested in the sponsor’s
central lab(s) to ensure consistency of lab measure-
ments for analysis and scientific review.
7. Consultation with clinical experts is recommended to
guide diagnostic testing and analysis of cases with
new onset or worsening liver injury during treatment
with a study drug or comparator/placebo. Narratives
of all cases including those with abnormalities that
are consistent with Hy’s Law should be assembled by
clinicians with appropriate expertise.
8. Liver injury strata of interest in each treatment arm
include those that are defined by the fold increases of
liver chemistry results above the upper limits of
normal, as described in Table 5. In studies of subjects
with pre-existing liver test abnormalities, these strata
might be defined by the fold increases of each
individual’s baseline test results.
9. The workshop did not draw a firm conclusion about
the value of serum GGT as a routine indicator to
characterize DILI cases in clinical trials.
10. With emerging pharmacogenomic markers of
increased susceptibility to drug-specific DILI, rele-
vant genomic test results, if available, should be
included as valuable data elements in the summaries
of possible DILI cases in clinical trials.
11. Graphic displays of study treatment population-level
data (study drug and comparator/placebo groups) should
be linked to individual graphic timelines that depict serial
biochemical measures in each study subject with acute or
worsening liver injury, irrespective of the presumed
etiology. Expert clinical narratives and time-linked
diagnostic studies that provide valuable information for
determining injury phenotype and causality should be
appended to these graphic timelines.
12. IT tools from sources such as CDISC should be used
in the preparation of clinical trial findings pertinent to
DILI analysis, in order to ensure complete and
uniformly collected data results.
4 Conclusion
Many of the recommendations made in the session on
required data elements and best practices for data collec-
tion and standardization are in alignment with those made
in other parallel sessions on methodology to assess clinical
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liver safety data, causality assessment for suspected DILI, and
liver safety assessment in special populations (hepatitis B, C,
and oncology trials). Nonetheless, a few outstanding issues
remain for future consideration. For example, reconciling
different options for study drug stopping rules in patients with
background liver diseases will require further discussion.
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